Pacira BioSciences (PCRX) Liabilities and Shareholders Equity (2010 - 2026)

Pacira BioSciences' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 23.83% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $5.3 billion, a 15.86% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 18.58% from the prior year.
• Liabilities and Shareholders Equity eased to $1.2 billion in Q1 2026 per PCRX's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.9 billion in Q1 2022 and bottomed at $1.2 billion in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.6 billion (2024), against an average of $1.6 billion.
• Across the five-year window, Liabilities and Shareholders Equity soared 46.91% in 2022 and fell 23.83% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then retreated by 6.35% to $1.6 billion in 2023, then decreased by 1.33% to $1.6 billion in 2024, then fell by 18.58% to $1.3 billion in 2025, then declined by 4.46% to $1.2 billion in 2026.
• Per Business Quant, the three latest PCRX Liabilities and Shareholders Equity figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025).